Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study

Martínez, E; Arranz, JA; Podzamczer, D; Lonca, M; Sanz, J; Barragán, P; Knobel, H; Ribera, E; Gutierrez, F; Valero, S; Clotet, B; Dalmau, D; Segura, F; Arribas, JR; Barrufet, P; Santos, I; Payeras, A; de Lazzari, E; Pich, J; Gatell, J

doi:10.1186/1758-2652-13-S4-P43

Journal of the International AIDS Society

Article metrics
Last updated: Thu, 25 Apr 2024 19:25:01 Z

Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study

Access & Citations

926

Article Accesses
0

Web of Science
0

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.